← brief for 2026-08-27 · Slowing decline

XIGDUO XR

Drug label A Peer reviewed Meta-analysis or large trial

Key takeaways

XIGDUO XR combines two diabetes drugs—dapagliflozin and metformin—and is approved for adults and children 10+ with type 2 diabetes. Dapagliflozin, one part of this combo, has been shown in large trials to slow kidney filtering rate decline by about 40%, cut the risk of needing dialysis or a transplant, and lower the chance of dying from heart problems. This approval means people with type 2 diabetes and kidney disease now have a proven option to protect their kidneys while managing blood sugar.

Who did this work

AstraZeneca Pharmaceuticals LP

Source

Drug label · openFDA, renal drug labels · 2026-08-11
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac8a0f7b-9f69-4495-abbc-3a47cd75a859